To provide compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy.
The invention relates to the compositions and methods for providing lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. Isomers of oxybutynin and its metabolites are also provided to meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for hyperactive bladder. Preferably, the composition may be administered in the form of an unoccluded or free form topically administered gel.
EBERT CHARLES D
| JPH08502952A | 1996-04-02 | |||
| JPH0640949A | 1994-02-15 | |||
| JPH1121240A | 1999-01-26 | |||
| JPH09255565A | 1997-09-30 | |||
| JP2002087964A | 2002-03-27 |
| WO2001080796A1 | 2001-11-01 | |||
| WO2001017472A1 | 2001-03-15 |
Yasushi Kobayashi
Akio Chiba
Hiroyuki Tomita
Next Patent: FORMULATION OF HUMAN ANTIBODY FOR TREATING OF DISEASE RELATED TO TNF-ALPHA